Johnson & Johnson

Total: $57.3 million

Top 2 drugs
Xarelto: $42 million
Stelara: $13.2 million
Watch the Xarelto TV commercial here >>

J&J didn't advertise a lot in the first half of 2013, but it backed two new drugs that have been coming on strong for it. Both its psoriasis drug Stelara and its anticoagulant Xarelto have done so well they were recently featured in FiercePharma's Top 15 Drug Launch Superstars. Stelara sales in the first half were $717 million, up 53% from the same time last year, while sales of Xarelto, which it shares with Bayer, grossed $347 million for J&J. That is more than a 355% jump from the $76 million sold in the same period the year before. Both drugs also figured prominently in J&J's third-quarter earnings, when pharmaceutical sales overall were up nearly 10%.

Johnson & Johnson

Suggested Articles

Merck & Co. joined the pack in 2018 by hiring Jim Scholefield as its first chief digital officer. Now, less than two years in, he's moving on.

Teva is counting on Austedo for growth amid challenges elsewhere, and this week, the drug failed two trials in Tourette syndrome.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.